Tag: medication

SCOTTSDALE, Ariz., June 16, 2025 (GLOBE NEWSWIRE) -- BlueGenes, a leading pharmacogenetics (PGX) solution, and Levrx Technology, a digital pharmacy engagement platform, have announced a strategic partnership. Together they aim to accelerate the adoption of personalized prescribing by seamlessly integrating genetic testing insights into pharmacy benefit systems.

Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools help life sciences brands engage, educate, and activate patients

Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax¹

BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.

Updated Virtual Weight Loss Platform Expands Access to GLP-1 Support and Clinician-Guided Obesity Care Across All 50 States